AADvac1 + LM11A-31 for Progressive Supranuclear Palsy

(PTP Trial)

This trial tests two experimental treatments, AADvac1 and LM11A-31, to determine their potential benefits for individuals with Progressive Supranuclear Palsy (PSP), a brain disorder affecting movement, balance, and eye movements. The trial aims to assess the safety and effectiveness of these treatments in managing PSP symptoms. Participants will receive either one of these treatments or a placebo, which is a harmless pill with no effect. Suitable candidates have experienced PSP symptoms for less than five years and can walk at least 10 steps with some assistance. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in PSP treatment.

The trial requires that you have stable doses of permitted medications for at least 30 days before screening. It doesn't specify which medications are permitted, so you should discuss your current medications with the trial team to see if they are allowed.

A previous study found AADvac1 to be safe. Most participants tolerated it well, experiencing only minor side effects such as injection site reactions and temporary confusion. No serious safety issues emerged.

Research on LM11A-31 also shows it is safe and well-tolerated. In trials involving individuals with mild to moderate Alzheimer's, it did not cause serious side effects. The side effects resembled those experienced by participants who took a placebo (a substance with no active ingredients).

Researchers are excited about AADvac1 and LM11A-31 because they offer innovative approaches to treating Progressive Supranuclear Palsy (PSP), a condition with limited current treatment options. Unlike traditional treatments that focus on symptom management, AADvac1 is designed to target and reduce tau protein buildup, a key factor in PSP progression. Meanwhile, LM11A-31 works differently by targeting nerve cell survival pathways, potentially preserving brain function. These therapies could represent a significant advancement by not only addressing symptoms but also potentially slowing or modifying the disease itself.

Research has shown that AADvac1, one of the treatments in this trial, produced positive results in treating Progressive Supranuclear Palsy (PSP). Specifically, studies found that AADvac1 slowed the increase of a protein called NfL, linked to nerve cell damage, suggesting it might help slow the disease. Meanwhile, LM11A-31, another treatment option in this trial, showed promise in early research for brain diseases. It has been safe and demonstrated early signs of aiding disease progression. Both treatments are being studied in separate arms of this trial for their potential to effectively manage PSP symptoms.²⁴⁶⁷⁸